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A Newly Discovered Fc Receptor
that Explains IgG-Isotype
Disparities in Effector Responses
a
The known IgG FcRs primarily mediate inflammation t
by interacting with IgG1, even though IgG2 isotypes c
tend to be more pathogenic. Nimmerjahn et al. (2005) m
thave just identified a novel FcR that binds IgG2 but
not IgG1, potentially explaining differences in biologi- a
fcal activity that are seen with various IgG isotypes
(Nimmerjahn et al., 2005). F
p
Receptors for the Fc portion of IgG (FcγRs) are essen- a
Itial mediators of the inflammatory effect of immune
complexes and cytotoxic antibodies. This function is k
Fcritical for effective clearance of pathogens, but it can
also result in the development of a variety of autoim- qune disorders brought about by IgG autoantibodies,
uch as autoimmune hemolytic anemia (AHA), idio-
athic thrombocytopenia purpura (ITP), and rheuma-
oid arthritis (RA). Additionally, Fc receptor engagement
lays a central role in the therapeutic use of cytotoxic
ntibodies for the treatment of infectious and neoplas-
ic diseases. These important functions of IgG Fc re-
eptors in triggering protective or autoimmune inflam-
atory responses have been revealed largely through
he characterization of mice deficient in FcγRs (Ravetch
nd Bolland, 2001). To date, three classes of receptors
or IgG have been identified in the mouse: FcγRI,
cγRIIB, and FcγRIII. These classes can themselves be
laced into two groups: the activating receptors FcγRI
nd FcγRIII, characterized by their association with an
TAM-containing signaling component that initiates a
inase activation cascade, and the inhibitory receptor
cγRIIB, characterized by the presence of an ITIM se-
uence that recruits inhibitory phosphatases that limit
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3effective signaling. FcR of the activating class bind IgG
either with relatively high affinity (108–109 M−1) in the
case of FcγRI or with such low affinity that they can
only bind aggregated immunoglobulin, as is the case
with FcγRIII. Because of FcγRI’s high affinity for IgG, its
binding sites are most likely always occupied with se-
rum monomeric IgG. This, and the fact that expression
of FcγRI is low in nonactivated cells, has made its phys-
iological role in triggering inflammatory responses
somewhat less clear than that of FcγRIII.
FcγRI shares the same ITAM-containing signal sub-
unit, the γ−chain, with all other activating Fc receptors.
This γ-subunit is not only necessary for surface assem-
bly and signaling by FcγRI and FcγRIII (IgG receptors)
but also by the FcRI (IgE) and FcαRI (IgA) receptors. γ
chain knockout mice are unable to mediate IgG-trig-
gered inflammatory responses in a large number of mu-
rine models of disease. For example, these mice do not
mount an effective antitumor response against a murine
metastatic melanoma when given anti-melanocyte anti-
bodies. They were also protected from the induction of
AHA by anti-red blood cell antibodies and were resis-
tant in experimental models of ITP that use mouse anti-
platelet antibodies to trigger thrombocytopenia. In the
case of RA pathogenesis in the K/BxN transgenic
model (Ji et al., 2002), anti-glucose-6-phosphate isom-
erase Igs can induce arthritis without the participation
of lymphocytes. Mice lacking the FcRγ chain are not sus-
ceptible to arthritis induction upon transfer of K/BxN
sera, whereas mice deficient only for FcγRIII (created
by deleting only the receptor α chain) have partially at-
tenuated responses and deletion of FcγRI α chain has
no effect on disease. While these data reveal a signifi-
cant role for FcγRIII in the induction of inflammatory
arthritis, they also imply the existence of another recep-
tor essential for this process that requires the FcRγ
chain for function and that is expressed by cells other
than lymphocytes.
How can these data be explained? In both human
and mouse models, certain IgG isotypes seem to be
more effective in cytotoxic therapies or more pathologi-
cal in the progression of autoimmune disease. These
differences have conventionally been attributed to dis-
parities in the ability of certain isotypes to engage com-
plement or one of the known FcγR, based mainly on
data from in vitro binding assays. However, in vivo
studies involving mice with deletion of specific FcRs
suggested a different possibility. In the AHA murine
model, IgG2a anti-erythrocyte antibodies exhibited the
highest pathogenicity (Fossati-Jimack et al., 2000) but
this difference in IgG isotype effectiveness was not to-
tally accounted for either by the differences in receptor
affinity among the Fc receptors known to date or by
complement binding. In vitro, it has been shown that
murine IgG1 and IgG2b interact preferentially with the
low affinity receptors FcγRIIB and FcγRIII, and IgG2a
with the high affinity receptor FcγRI. Also in vitro, phago-
cytosis of IgG1—but not IgG2a—or IgG2b-coated sheep
red blood cells by macrophages requires FcγRIII (Ha-
zenbos et al., 1996) . In vivo, FcγRIII-deficient mice were
resistant to disease induced by an anti-platelet anti-
body of the IgG1 subclass but were not protected from
disease when the antibody was of the IgG2a subclass.
Similar results were obtained in AHA and anti-tumor re-sponses (Meyer et al., 1998; Fossati-Jimack et al., 2000;
Hazenbos et al., 1998). FcγRI deletion also did not con-
fer effective protection in these autoimmune models
(Ioan-Facsinay et al., 2002). A possible answer to all
these unexplained results now comes from the discov-
ery of a novel murine Fc receptor with preference for
the IgG2a subclass, as reported by Nimmerjahn et al.
(2005) in this issue of Immunity. This novel receptor for
IgG, named FcγRIV, is expressed on myeloid cells but
not on lymphocytes or NK cells. Significantly, FcγRIV
binds IgG2a and IgG2b with at least 10-fold higher af-
finity than does FcγRIII, but it does not bind IgG1 with
measurable affinity. Murine FcγRIV shares the highest
homology with human FcγRIII (63% sequence identity)
and it associates with the FcRγ chain like all other acti-
vating FcRs. The gene for FcγRIV in the mouse is lo-
cated on chromosome 1, just between the two low af-
finity receptors FcγRIIB and FcγRIII. Because this
receptor is constitutively expressed on myeloid cells at
high levels and it binds IgG2a with intermediate affinity,
it can provide an explanation for the increased patho-
genicity of cytotoxic antibodies of the IgG2a isotype.
Indeed, Nimmerjahn et al. (2005) have tested this hy-
pothesis by using FcγRIV blocking antibodies when as-
sessing ITP induction with different IgG isotypes. As
anticipated by the isotype binding preference of this
newly discovered FcR, FcγRIV blocking antibodies re-
duced thrombocytopenia resulting from injection of
IgG2b and IgG2a anti-platelet antibodies but not the
disease resulting from administration of antibodies of
IgG1 isotype. These data suggest an important role of
FcγRIV in IgG2-induced inflammatory responses and it
is expected that confirmation of this role will come in
the future with the characterization of mice with selec-
tive inactivation of the gene encoding the α chain of
this receptor. Overall, the finding that individual FcγRs
interact differently with IgG isotypes in mediating auto-
immune injury and protective inflammatory responses
is certainly relevant for the potential use of these recep-
tors as therapeutic targets in the treatment of autoim-
mune disease in humans.
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